ClinicalTrials.govpublic full text
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
acute myeloid leukemia, myelodysplastic syndrome, maintenance treatment, stem cell transplant, cytarabine-based chemotherapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 805677
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.